RNS Number : 4148V
NetScientific PLC
30 January 2017



("NetScientific" or the "Company" or the "Group")


Grant of Options to Directors


London, UK - 30th January 2017 - NetScientific plc ("NetScientific", AIM: NSCI), the transatlantic biomedical and healthcare technology group, today announced that on 27th January 2017, options over ordinary shares of 5p each were granted to its CEO François Martelet and CFO Ian Postlethwaite as detailed below (the "New Options").



   Number of Options

Number of Options

François Martelet

Ian Postlethwaite






The New Options have an exercise price of 65.5 pence per share, being the average closing price for the ordinary shares over the five dealing days prior to the date on which the options were granted. The New Options vest three years from the date of grant.



- Ends -



For more information, please contact:



François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO


 Tel: +44 (0)20 3514 1800

Stifel Nicolaus Europe Limited (NOMAD and broker)

Jonathan Senior / David Arch / Ben Maddison

 Tel: +44 (0) 20 7710 7600


Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson / Chris Welsh


 Tel: +44 (0)20 3709 5700



About NetScientific Plc


NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

This information is provided by RNS
The company news service from the London Stock Exchange